US Corporate Distress Financial Stress SEC Filings — April 07, 2026

07-04-2026

NXG NextGen Infrastructure Income Fund issued a Notice of Guaranteed Delivery (EX-99.1) for its rights offering under the Prospectus Supplement dated April 6, 2026, and accompanying Prospectus dated July 9, 2025. The form facilitates subscription for common shares via primary subscription and over-subscription privilege, with submissions required by 5:00 p.m. ET on the Expiration Date of April 30, 2026, to Subscription Agent Equiniti Trust Company, LLC. No financial performance metrics or period comparisons are provided in the filing.

• ·Subscription delivery addresses: 55 Challenger Road, Suite #200, Ridgefield Park, New Jersey 07660, Attn: Reorganization Department
• ·Information Agent contact: (800) 207-2872
• ·Guaranteed delivery must be followed by Subscription Certificate by close of business on the first business day after Expiration Date

07-04-2026

Opus Genetics announced a strategic financing agreement with Oberland Capital providing up to $155 million in non-dilutive funding via notes, including an initial $35 million tranche and a concurrent $5 million equity investment at $4.48 per share, boosting current cash to approximately $100 million and extending the runway into 2029 to fund pivotal studies for OPGx-LCA5 and OPGx-BEST1. The deal supports accelerating three earlier-stage programs—OPGx-RDH12 (clinic Q4 2026), OPGx-MERTK (end 2026), and OPGx-RHO (2027)—with topline results from OPGx-BEST1 Phase 1/2 Cohort 1 on track for mid-2026. No declines or flat metrics reported; financing terms include 7-year maturity, ~4.1% initial cash interest rate, and partial convertibility.

• ·Initial closing expected April 20, 2026; notes mature 7 years from issuance with 6-year interest-only period and 50% repayment on 6th anniversary.
• ·Notes: floating rate with floor/cap; 50% interest paid-in-kind first 8 quarters; up to 10% principal convertible at $6.72/share.
• ·Additional $35M tranche available on or prior to March 31, 2028 upon LCA5 regulatory milestones.
• ·RDH12 partially funded by RDH12 Alliance; MERTK collaboration with Department of Health - Abu Dhabi.

07-04-2026

The U.S. Bankruptcy Court for the Southern District of Texas confirmed the Fourth Amended Chapter 11 Plan of Liquidation for Luminar Technologies, Inc. and its four affiliated debtors on April 3, 2026, following a confirmation hearing on April 1, 2026, with all objections overruled. The debtors filed voluntary Chapter 11 petitions on December 15 and 31, 2025 (Case No. 25-90807), and have operated as debtors in possession since then. The plan proceeds to liquidation, marking a significant adverse development with no ongoing operations highlighted.

• ·Chapter 11 Cases jointly administered under Case No. 25-90807 (CML) in the Southern District of Texas Houston Division
• ·Creditors’ Committee appointed by U.S. Trustee on December 30, 2025
• ·Debtors’ mailing address: 2603 Discovery Drive, Suite 100, Orlando, Florida 32826
• ·Confirmation Hearing held April 1, 2026; Voting and Objection Deadline March 23, 2026

07-04-2026

Four Corners Property Trust (NYSE: FCPT) entered into a new seven-year $200 million senior unsecured delayed draw term loan facility maturing on April 6, 2033, with $50 million drawn at close for immediate investments and general corporate purposes, and the remaining $150 million available for future acquisitions expected in late Q2 and early Q3 2026. The facility is priced at 1.25% over SOFR, supported by BBB/Baa3 ratings, with 96% of term loans hedged and overall debt 98% fixed-rate through November 2027; pro forma run-rate leverage is approximately 5.4x within the 5.0x-6.0x target range. Executives highlighted the attractive pricing and flexibility for accretive investments at 200+ basis points spreads.

• ·Term Loan Facility credit margin: 1.25% over SOFR.
• ·Maturity date: April 6, 2033.
• ·Current senior unsecured debt ratings: BBB (Fitch) / Baa3 (Moody’s).
• ·Stated net leverage range: 5.0x-6.0x.
• ·Facility led by The Huntington National Bank as Administrative Agent.

07-04-2026

On April 1, 2026, Partners Group Lending Fund, LLC entered into an Amended and Restated Expense Support and Conditional Reimbursement Agreement with Partners Group (USA) Inc., amending the original agreement from August 31, 2023, by changing the Expense Limitation for Other Operating Expenses to 1.00% (annualized) of the Fund's net asset value instead of Aggregate Capital Commitments. The Adviser will waive the Base Management Fee and pay or absorb expenses to meet this cap, with the Fund required to reimburse waived amounts over up to three years if it remains in compliance. The agreement has a one-year term and automatically renews annually unless terminated with 30 days' notice.

• ·Agreement terminates automatically upon termination of Investment Advisory Agreement, Fund dissolution/liquidation, or public listing/liquidity event.
• ·Reimbursement must not cause Fund to exceed Expense Limitation and is extinguished after three years if not repaid.
• ·Unitholders are third-party beneficiaries with enforcement rights.

07-04-2026

GT Biopharma, Inc. entered into an Investigator Initiated Clinical Trial Agreement with the Regents of the University of Minnesota on April 3, 2026, under which the University will sponsor an IND application (IND 169118) for GTB-5550 and conduct a phase 1a/1b clinical trial titled 'GTB-5550, a Camelid Nanobody B7-H3 Tri-Specific Killer Engager (camB7-H3 TriKE®), in Select Advanced Solid Tumors That Failed Prior Therapy.' The Company will bear the costs of up to approximately $3.8 million over three years for the study, with both parties having rights to publish results and standard termination provisions including 30 days' notice or immediate for safety reasons.

• ·IND number: 169118
• ·Agreement termination: 30 days' written notice, immediate by University for health/safety, or for material breach uncured within 30 days

07-04-2026

Kiora Pharmaceuticals closed a private placement on April 6, 2026, providing up to $24 million in gross proceeds, including $5.0 million upfront funding from sole investors Perceptive Advisors (new) and ADAR1 Capital Management, with up to an additional $19 million upon exercise of milestone-based warrants. Proceeds will support general corporate purposes, business operations, strategic business development, and ongoing R&D for retinal disease therapies like KIO-301 and KIO-104. The transaction was priced at-the-market under Nasdaq rules with no placement agent engaged.

• ·Tranche A-1 warrants: initial 9-month term, reduces to 30 days upon strategic transaction expanding market opportunity.
• ·Tranche A-2 warrants: initial 4-year term, reduces to 30 days upon any asset completing Phase 3 enrollment.
• ·Pre-funded warrants issued in lieu of common stock at $2.543 minus $0.0001 exercise price.
• ·Company to file SEC registration statement for resale of shares and warrant shares.
• ·Transaction closed April 6, 2026, under Section 4(a)(2)/Regulation D; securities unregistered.

07-04-2026

On April 1, 2026, Boxlight Corporation amended its inventory finance agreement with J.J. Astor & Co., converting $556,200 of outstanding balance into 600,000 shares of common stock at a conversion price of $0.927 per share. The amendment includes 'Proceeds Protection,' obligating the Company to pay any shortfall in cash if aggregate proceeds from J.J. Astor's sale of the shares fall below $556,200 within five trading days. Michael Pope, Boxlight's Board Chairman and former CEO, is CEO of J.J. Astor, which is owned by a fund he manages.

• ·Amendment to inventory finance agreement originally dated May 27, 2025, and restated on November 7, 2025.
• ·Proceeds Protection requires cash payment of shortfall within five (5) Trading Days.

07-04-2026

Hydrofarm Holdings Group, Inc. (HYFM) received a Nasdaq notice on April 1, 2026, for non-compliance with Listing Rule 5550(b)(1) due to a stockholders’ deficit of ($63,296,000) as of December 31, 2025, below the $2.5 million minimum, and failure to meet alternative standards of $35 million market value or $500,000 net income. The company's common stock remains listed and traded under 'HYFM' with no immediate delisting, but it has until May 16, 2026, to submit a compliance plan, potentially extendable to September 28, 2026. The company is evaluating options but provides no assurance of regaining or maintaining compliance.

• ·Notification received April 1, 2026; 45 calendar days to submit plan (until May 16, 2026); possible 180-day extension (until September 28, 2026).
• ·Compliance checked against Form 10-K filed March 27, 2026, and as of March 31, 2026.
• ·Right to appeal to Nasdaq hearings panel if plan rejected, staying any delisting.

07-04-2026

Flowers Foods, Inc. entered into a Term Loan Credit Agreement dated April 6, 2026, with various lenders, Wells Fargo Bank, National Association as administrative agent, Bank of America, N.A. and Royal Bank of Canada as co-syndication agents, and others as co-documentation agents and joint lead arrangers. The agreement establishes a term loan facility with initial applicable margins of 0.375% for Base Rate Loans and 1.375% for SOFR Loans, and a ticking fee of 0.175%, with pricing adjusting based on leverage ratio levels and debt ratings per a pricing grid. It includes standard covenants such as maximum leverage ratio and minimum interest coverage ratio, conditions precedent, representations, warranties, and events of default, with no specific commitment amounts or funding dates disclosed in the filing.

• ·Filing date: April 07, 2026
• ·2026 Notes issued pursuant to Indenture dated April 3, 2012
• ·Pricing grid includes Level VII at 1.000% Base Rate margin, 2.000% SOFR margin, 0.250% ticking fee if Debt Rating Ba2/BB or below
• ·Negative covenants include limits on liens, indebtedness, restricted payments, and transactions with affiliates

07-04-2026

Direct Digital Holdings, Inc. received a Nasdaq Staff Delisting Determination on April 2, 2026, for failing Listing Rule 5550(b)(1) with a stockholders’ equity deficit of $7.0 million versus the required minimum of $2.5 million, and not meeting alternative standards of $35 million market value of listed securities or $500,000 net income. Although the company recently complied with the Bid Price Rule on February 12, 2026, it remains under a discretionary Panel Monitor through February 12, 2027, with no further compliance extensions allowed. The company intends to request a hearing by April 9, 2026, but success is uncertain.

• ·Nasdaq Hearings Panel granted exception through January 30, 2026, for Bid Price Rule compliance on November 7, 2025.
• ·Under Panel Monitor per Listing Rule 5815(d)(4)(A), no compliance plans or cure periods allowed for future deficiencies through February 12, 2027.

07-04-2026

American Healthcare REIT, Inc. and its subsidiaries entered into a Second Amendment to the Second Amended and Restated Credit Agreement effective April 1, 2026, amending terms via Annex I (not provided), adding multiple subsidiary guarantors, and terminating the revolving commitments of exiting lender Barclays Bank PLC upon full payment of its obligations. The amendment facilitates reallocation of outstanding revolving loans among remaining lenders, including Bank of America, N.A. as Administrative Agent, with conditions precedent confirming no Default or Event of Default post-amendment. No specific financial metrics or changes in borrowing capacity were disclosed.

• ·Original Credit Agreement dated February 14, 2024; First Amendment dated December 9, 2024.
• ·Legal opinion provided by Clifford Chance US LLP.

07-04-2026

Nabors Industries Ltd (Holdings) and Nabors Industries, Inc. (Borrower) entered into an Incremental Joinder to their Amended and Restated Credit Agreement dated June 17, 2024, establishing a $25,000,000 incremental commitment from BOKF, NA dba Bank of Texas, increasing the US Dollar Letters of Credit Maximum Amount from $125,000,000 to $150,000,000. This amendment enhances the company's letter of credit capacity pursuant to Section 2.23 of the Credit Agreement. No declines or flat metrics are reported; the change represents a 20% increase in the facility limit.

• ·Joinder becomes effective upon receipt of executed counterparts, expense reimbursement, true and correct representations and warranties, no Default or Event of Default, pro forma covenant compliance, and officer certificates.
• ·Amends recitals, adds 'Joinder Effective Date' definition, restates 'Letters of Credit Maximum Amount' definition, and updates Schedule V.
• ·Governed by New York law; constitutes a Loan Document.

07-04-2026

New Fortress Energy Inc., through its subsidiary NFE Power PR LLC, completed the sale of certain turbines (Equipment) to Macquarie Energy LLC for $265,882,500 on April 1, 2026, as part of a sale-leaseback transaction. NFE Turbines LLC, another subsidiary, entered into a 10-year Master Lease Agreement to lease the Equipment back from Macquarie, expected to commence on July 1, 2026, with the parent company providing guarantees for both agreements. The net proceeds were used to repay certain indebtedness, providing immediate liquidity while introducing a long-term lease obligation.

• ·Transaction reported under Items 1.01 (Entry into Material Definitive Agreement) and 2.03 (Creation of Direct Financial Obligation)
• ·Lease term: 10 years
• ·Lease expected to begin: July 1, 2026
• ·Company provides parent guarantee for Lessee’s obligations under the Lease and Seller’s obligations under the Purchase Agreement

07-04-2026

Genie Energy Ltd. received a notice of noncompliance from the NYSE on April 1, 2026, stating failure to satisfy Section 802.01E due to delayed filing of its Form 10-K for the fiscal year ended December 31, 2025. The delay results from the need to restate audited financial statements for the years ended December 31, 2024, and 2023, as previously disclosed in a Form 12b-25 filed on March 16, 2026. The company issued a press release on April 7, 2026, announcing the notice.

• ·Securities registered: Class B common stock, par value $0.01 per share, trading symbol GNE on NYSE.
• ·Principal executive offices: 520 Broad Street, Newark, New Jersey 07102.
• ·Form 8-K items reported: 3.01, 7.01, 9.01.

07-04-2026

On April 7, 2026, the Board of Directors of America’s Car-Mart, Inc. approved the closure of 42 out of 136 dealership locations (reducing to 94 across 12 states by April 14, 2026) due to delays in establishing a non-recourse revolving warehouse credit facility amid capital constraints. The company expects a $14 million non-cash impairment charge in Q4 FY2026 related to assets at closing locations, with additional unestimated cash charges for employee separations and lease exits. While prior successes included a $300 million term loan in October 2025 and a ninth securitization in December 2025, current market conditions have prolonged warehouse facility alignment.

• ·Closures expected to be completed by April 14, 2026.
• ·Impairment charge relates to right-of-use lease assets, leasehold improvements, and other fixed assets; preliminary and subject to change.
• ·Additional cash charges for employee separation costs and lease exit costs unestimated at this time.
• ·Q4 FY2026 ends April 30, 2026.

07-04-2026

MGM Resorts International entered into a Voting Agreement on April 3, 2026, with IAC Inc. and Barry Diller, requiring IAC, Diller, and their affiliates (Covered Entities) to vote Excess Voting Securities exceeding 25.73% of the Company's total voting power in proportion to non-Covered stockholders. The agreement supports IAC's designation of up to two Qualified Directors for the Board and terminates upon Covered Entities owning less than 17.5% of voting securities, failure to meet nomination conditions, or a change of control. No financial impacts or performance metrics are disclosed.

• ·Agreement termination also occurs if Board fails Nomination Condition or upon Company change of control.
• ·Diller Entities excluded from voting restrictions once Diller ceases IAC Chairman/Senior Executive role and owns <1/3 of IAC voting power.
• ·As of agreement date, Barry Diller deemed designated by IAC for Board service.
• ·Voting applies to annual/special stockholder meetings or actions by written consent.

07-04-2026

Wellgistics Health, Inc. entered into a Note Purchase Agreement dated April 1, 2026, for a private offering of promissory notes with an aggregate principal amount of up to $1,250,000 and an aggregate purchase price of $1,000,000. The agreement involves Dawson James Securities, Inc. as Placement Agent and is subject to closing conditions including representations, warranties, and delivery of executed documents. No financial performance metrics or period-over-period comparisons are provided in the filing.

• ·Agreement closing to occur remotely via exchange of documents on or around April 1, 2026.
• ·Notes subject to Nasdaq rules limiting Common Stock issuance without stockholder approval.
• ·Company represents no outstanding Indebtedness except as disclosed on Schedule 7.4 and no Liens except as on Schedule 7.5.

07-04-2026

WM Technology, Inc. (Nasdaq: MAPS) announced its voluntary delisting of Class A common stock and warrants from Nasdaq, with Form 25 filing expected around April 17, 2026, and last trading day around April 24, 2026, followed by Form 15 to suspend SEC reporting. The Board cited benefits like reduced regulatory burdens and greater operational agility in the cannabis industry for long-term value creation. However, the move highlights challenges including limited liquidity, lack of investor interest, and potential reduced trading volume and volatility on OTC markets.

• ·Company founded in 2008 and headquartered in Irvine, California.
• ·Expects securities to be quoted on OTC markets post-delisting, but no guarantee of broker market-making.
• ·Forward-looking statements include risks like market reactions, lower liquidity on OTC, and ongoing litigation/regulatory issues.

07-04-2026

Tianci International, Inc. (CIIT) received a Nasdaq deficiency notice on October 29, 2025, for its common stock closing bid price being below the $1.00 minimum for 30 consecutive business days under Listing Rule 5550(a)(2), with a compliance deadline of April 27, 2026. On April 6, 2026, Nasdaq informed the company that it has regained compliance with the Bid Price Requirement. The matter is now closed with no further action required.

• ·Securities: Common Stock, par value $0.0001, Trading Symbol CIIT
• ·Nasdaq Listing Rule: 5550(a)(2) (Bid Price Requirement)
• ·Compliance grace period: 180 calendar days
• ·Company address: Unit 1109, Lippo Sun Plaza, 28 Canton Road, Tsim Sha Tsui, Kowloon, Hong Kong 999077
• ·Former names: Steampunk Wizards, Inc. (changed 20150702), FREEDOM PETROLEUM INC. (changed 20120910)

07-04-2026

Richtech Robotics Inc. entered into a Purchase and Sale Agreement on April 1, 2026, with PSIF EBS Rainbow LLC to acquire an approximately 79,325 square foot building located at 9530 S. Rainbow Blvd., Las Vegas, Nevada 89139, for a purchase price of $21,180,000, inclusive of $600,000 earnest money. The Company plans to use the property as a U.S.-based facility for warehousing, assembly, light manufacturing, research and development, testing, and robotics-driven data collection to support its robotics and AI systems. Closing is targeted for 15 days after the expiration of a 45-day inspection period, subject to customary conditions, representations, warranties, and the Company's right to terminate during the inspection period.

• ·Inspection Period ends 45 days after April 1, 2026
• ·Closing Date targeted as the 15th day after Inspection Period expiration
• ·Property address: 9530 S. Rainbow Blvd., Las Vegas, Nevada 89139

07-04-2026

The Board of Directors of Visium Technologies, Inc. unanimously accepted the immediate resignations of independent directors Paul Anthony Favata and Thomas Grbelja from all positions, including Audit, Compensation, and Nominating Committees, as part of a board refresh tied to strategic restructuring and acquisition transactions announced in a March 29, 2026 LOI; no disagreements with company operations were noted. The Board authorized filing Certificates of Designation for up to 50,000,000 shares of Series A Convertible Preferred Stock (stated value $750 per share) and 30,000,000 shares of Series B (stated value $375 per share), cancelled the Series C Preferred Stock (zero shares outstanding), and adopted strict 'Conversion Gates' requiring extensive proofs, audits, bonds, and court judgments before any conversions. These actions address legacy governance issues from prior reincorporation and aim to protect against unauthorized dilutions.

• ·Series A conversion: one-to-one into common stock subject to variable adjustment (effective ratio ~21,428.57 common shares per Series A share); Series B: 300 Series B shares into one common share.
• ·Resignations effective April 7, 2026; tied to LOI dated March 29, 2026.
• ·Conversion Gates include 11 cumulative conditions, non-waivable without Board resolution, enforced by transfer agent.

07-04-2026

Transportation and Logistics Systems, Inc. (TLSS) entered into a Member Interest and Asset Exchange Agreement on April 1, 2026, for a reverse triangular merger to acquire 80% membership interest in Patriot Glass Solutions, LLC (PGS) and four nanotechnology patents from Badcer Ops, Inc. for $4,750,000 payable in 47,500 shares of Series J Senior Convertible Preferred Stock. PGS provides window tinting and C-Bond glass strengthening solutions through a network of more than 50 dealers, aligning with TLSS's strategy to expand in safety and security technology. Closing is expected by June 1, 2026, subject to due diligence, financial statements, and other conditions; no financial performance data or comparisons were provided.

• ·Michael Wanke to enter employment agreement with PGS as closing condition
• ·Closing conditions include audited PGS financials for year-end 2024 and 2025, unaudited Q1 2026 financials, due diligence, landlord consent for lease assignment
• ·Seller shareholders: Jeff Badders and Mercer Street Global Opportunity Fund, LLC (existing TLSS preferred stockholder)

07-04-2026

TransCode Therapeutics, Inc. (RNAZ) entered into financing agreements with an institutional healthcare investor for up to $20 million, comprising up to $6 million in pre-paid advances via convertible promissory notes and a three-year Standby Equity Purchase Agreement (SEPA) for up to $14 million in common stock sales. This extends the company's runway into late 2027/early 2028 to support the Phase 2a trial of lead candidate TTX-MC138, expected to begin in Q2 2026. An initial $1 million note will issue with the 10-K for year ended December 31, 2025, with an additional $5 million note subject to shareholder approval.

• ·Convertible promissory notes accrue 5% simple annual interest and may convert into common stock.
• ·Tungsten Advisors acted as Sole Placement Agent.
• ·Phase 0 trial showed delivery to metastatic lesions and pharmacodynamic activity; Phase 1a met safety endpoint.
• ·Additional $5 million note issuance requires shareholder approval per Nasdaq rules.

07-04-2026

On April 2, 2026, Bitmine Immersion Technologies, Inc. entered into Amendment No. 1 to the employment agreements of CEO Chi Tsang (original date November 20, 2025) and CFO/COO Young Kim (original date January 7, 2026), adding annual long-term incentive awards with target values of $500,000 for Tsang (60% RSUs, 40% options) and $1,750,000 for Kim (100% options, prorated for FY2026). Both awards are granted under the 2025 Omnibus Incentive Plan, with quantities based on VWAP over 10 trading days prior to grant (options multiplied by factor of 3), exercise price at fair market value, and vesting in four equal quarterly 25% installments over one year, subject to continued employment.

• ·Tsang Awards: 60% RSUs, 40% Options; Kim Awards: 100% Options.
• ·Unvested awards forfeit upon termination unless specified in Section 8 of original agreements.
• ·Exhibits 10.1 (Tsang Amendment) and 10.2 (Kim Amendment) filed.

07-04-2026

Prairie Operating Co. entered into an Amendment and Restatement to its Securities Purchase Agreement, originally involving the sale of 148,250 shares of Series F Preferred Stock with a $1,000 stated value per share. The amendment shifts the Anniversary Warrant Issuance Date from April 7, 2026, to April 9, 2026, and requires a $3 million payment to buyers on April 9, 2026, unless waived. Warrants will allow purchase of common stock shares equal to 125% of the aggregate stated value divided by the average 10-day VWAP prior to original issuance.

• ·Amendment dated April 6, 2026, references prior Purchase Agreement from March 26, 2025 filing and Original Amendment dated March 25, 2026.
• ·Exhibit 10.1 contains full Amendment and Restatement text.

07-04-2026

Accuray Incorporated entered into an amendment to its Consulting Agreement with Dedication Capital, LLC, an affiliate of board member Steven F. Mayer, on April 1, 2026, reducing cash compensation components by 50% for periods after March 31, 2026, through October 31, 2026, including the Base Consulting Fee and minimum cash incentive awards for FY ended June 30, 2026, and Q ended September 30, 2026. Equity vesting terms were modified, satisfying time-based vesting for 916,336 Initial Restricted Shares and 100% of PSAs as of April 1, 2026, with the remaining 333,004 Initial Restricted Shares vesting on October 31, 2026, and the End Date extended to that date. The amendment is expected to result in at least $362,500 in cash savings to the Company.

• ·Amendment filed as Exhibit 10.1.
• ·Original Consulting Agreement dated October 18, 2025.

07-04-2026

AB CRE PDF LENDING C LLC (Seller) and AB COMMERCIAL REAL ESTATE PRIVATE DEBT FUND, LLC (Guarantor) entered into a First Amendment to the Master Repurchase Agreement with Citibank, N.A. (Buyer), dated April 1, 2026, extending the Stated Termination Date to April 1, 2028 from the original April 1, 2025 agreement. Seller and Guarantor reaffirmed all obligations under the Repurchase Agreement, Guaranty, and other Transaction Documents, with no Events of Default reported. The amendment maintains all other terms in full force and effect.

• ·Original Master Repurchase Agreement dated April 1, 2025
• ·Guaranty dated April 1, 2025
• ·Effectiveness subject to executed documents and payment of Buyer's costs and expenses
• ·No changes to governing documents of Seller or Guarantor

07-04-2026

On April 1, 2026, Octave Specialty Group, Inc. entered into the First Amendment to its Credit Agreement, adding a $40,000,000 term loan to the existing facility, resulting in total outstanding term loans of $139,375,000 with the same maturity and interest rate. Proceeds from the Additional Term Loan will fund Cirrata UK’s obligation to honor put rights exercised in March 2026 by minority shareholders of Octave Specialty Limited. The Company also pledged its ownership interests in Everspan Holdings, LLC in connection with the amendment.

• ·Original Credit Agreement dated October 31, 2025.
• ·First Amendment executed with lenders and Truist Bank as Administrative Agent.
• ·Full text of First Amendment to be filed as exhibit to 10-Q for quarter ended June 30, 2026.